Hepatitis C virus replication inhibitor - Isis/Merck & Co

Drug Profile

Hepatitis C virus replication inhibitor - Isis/Merck & Co

Latest Information Update: 16 Mar 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Isis Pharmaceuticals; Merck & Co
  • Class Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 05 Dec 2006 Phase-I clinical trials in Hepatitis C in USA (PO)
  • 22 Nov 2004 A preclinical study has been added to the pharmacokinetics section
  • 07 May 2003 Profile updated with information presented at the 16th International Conference on Antiviral Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top